Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|January 15, 2002

BioPharm International

  • BioPharm International-01-01-2002
  • Volume 15
  • Issue 1

Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation

by Naidong Weng and Timothy D.J. Halls, Covance Laboratories, Inc. Meeting the challenges of large-scale LC/MS/MS can improve the analytical processes that support biopharmaceutical drug development. The conclusion of this article presents troubleshooting techniques for LC/MS/MS and illustrates an automation strategy.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 25 years ago

Outsourcing Outlook: E-Sourcing, Internet Facilitates Flexible Collaboration

almost 25 years ago

Inside Washington: Biotechnology in the Limelight, the Year Ahead

almost 25 years ago

Your Vested Interests: The War of the West

almost 25 years ago

Statistics for Laboratory Method Comparison Studies

almost 25 years ago

From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continues

almost 25 years ago

Liposomes (a Review): Part Two, Drug Delivery Systems

almost 25 years ago

Information Age Audits

almost 26 years ago

Considerations During Development of a Protein A-Based Antibody Purification Process

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more